

**Appendix I showing amendments to claims added during prosecution**

42. The amplification method of claim [41] 1 wherein said amplifying in vitro [the amplification] is linear or exponential.
43. The amplification method of claim 42 wherein said amplifying in vitro [the amplification] is exponential.
44. The amplification method of claim [41] 1 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] with [a polymerase and] at least one oligonucleotide primer.
45. The amplification method of claim 44 wherein [the amplification] said amplifying in vitro is linear or exponential.
46. The amplification method of claim [41] 1 wherein [the target polynucleotide is amplified with more than one polymerase] said amplifying in vitro comprises amplifying said separated target polynucleotide with more than one polymerase.
48. The detection method of claim [47] 7 wherein [the amplification] said amplifying in vitro is linear or exponential.
49. The detection method of claim 48 wherein [the amplification] said amplifying in vitro is exponential.
50. The detection method of claim [47] 7 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] with [a polymerase and] at least one oligonucleotide primer.
51. The detection method of claim 50 wherein [the amplification] said amplifying in vitro is linear or exponential.
52. The detection method of claim [47] 7 wherein [the target polynucleotide is amplified with more than one polymerase] said amplifying in vitro comprises amplifying said separated target polynucleotide with more than one polymerase.
64. The method of claim 1 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] non-specifically [with random primers].

06533906-071601

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

65. The method of claim 1 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] specifically [with specially tailored primers].
66. The method of claim 7 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] non-specifically [with random primers].
67. The method of claim 7 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] specifically [with specially tailored primers].
71. The method of claim 70 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] non-specifically [with random primers].
72. The method of claim 70 wherein said amplifying in vitro comprises amplifying said [the] separated target polynucleotide [is amplified] specifically [with specially tailored primers].

09533906.071601

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com